Issues in regulatory guidelines for data monitoring committees

Clinical Trials

Volumn 1, Issue 2, 2004, Pages 162-169

  Demets, David ^a   Califf, Robert ^b   Dixon, Dennis ^c   Ellenberg, Susan ^d   Fleming, Thomas ^e   Held, Peter ^f   Julian, Desmond ^g   Kaplan, Richard ^h   Levine, Robert ⁱ   Neaton, James ^j   Packer, Milton ^k   Pocock, Stuart ^l   Rockhold, Frank ^m   Seto, Belinda ⁿ   Siegel, Jay ^o   Snapinn, Steve ^p   Stump, David ^m   Temple, Robert ^d   Whitley, Richard ^q  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f ASTRAZENECA R AND D   (Sweden)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

^l LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^m GLAXOSMITHKLINE   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

^o CENTOCOR INC   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; REVIEW; STANDARD; UNITED STATES;

CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; GUIDELINES; HUMANS; RESEARCH SUPPORT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33744813860     PISSN: 17407745     EISSN: None     Source Type: Journal    
DOI: 10.1191/1740774504cn019xx     Document Type: Article

References (34)

1. Shalala D. Protecting research subjects - what must be done. New Engl J Med 2000; 343: 808-810.
2. National Institutes of Health. NIH policy for data and safety monitoring. NIH Guide, June 10, 1998. Retrieved 11 February, 2004, From: http://grants.nih.gov/grants/guide/notice-files/not98-084.html
3. US Food and Drug Administration Draft Guidance for Clinical Trial sponsors on the establishment and operation of Clinical Trial Data Monitoring Committees. Rockville, MD: FDA. 2001. Retrieved 11 February, 2004, From: http://grants.nih.gov/grants/guide/notice-files/not98-084.html
4. Ellenberg S., Fleming T., DeMets D. Data monitoring committees in clinical trials: a practical perspective. West Sussex, England: John Wiley & Sons, Ltd., 2002.
5. Greenberg Report: Organization, review, and administration of cooperative studies. Control Clin Trials 1988; 9: 137-148.
6. Coronary Drug Project Research Group. The coronary drug project: design, methods, and baseline results. Circulation 1973; 47(Suppl 1): 11-179.
7. Canner P.L. Monitoring of the data for evidence of adverse or beneficial treatment effects. Control Clin Trials 1983; 4: 467-483.
8. Ellenberg S.S., Geller N.L., Simon R., Yusuf S. (eds). Proceedings of ‘Practical Issues in Data Monitoring of Clinical Trials’ Bethesda, Maryland, U.S.A. 27-28 January 1992. Stat Med 1993; 12: 415-616.
9. DeMets D.L., Fleming T.R., Whitley R.J., et al. The Data and Safety Monitoring Board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials 1995; 16: 408-421.
10. Geller N.L., Stylianou M. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH. Stat Med 1993; 12: 543 -551; discussion 553.
11. US Department of Health and Human Services. Food and Drug Administration. Center for Devices and Radiological Health. Code of Federal Regulations. Title 21, Volume 1, Part 50-Protection of Human Subjects; Subpart B-Informed Consent of Human Subjects. April 1, 2003.
12. US Food and Drug Administration. Guideline for the format and content of the clinical and statistical sections of an application. Rockville, MD. July 1988. Retrieved 11 February, 2004, from: http://www.fda.gov/cder/guidance/statnda.pdf
13. International Conference on Harmonisation. Guideline for good clinical practice. Guideline E6. 1996. Retrieved 11 February, 2004, from: http://www.mcclurenet.com/FedRegisterPDFs/E6.pdf
14. International Conference on Harmonisation. Draft guideline on statistical principles for clinical trials. Guideline E9. 1998. Retrieved 11 February, 2004, from: http://www.mcclurenet.com/FedRegisterPDFs/E9.pdf
15. US Department of Health and Human Services. Office of Inspector General. Protecting Human Research Subjects. Status of Recommendations. Office of Inspector General Report. April 2000 OEI-01-97-00197. Retrieved 11 February, 2004, from: http://oig.hhs.gov/oei/reports/oei-01-97-00197.pdf
16. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. November 1995.
17. Sugarman J. The role of institutional support in protecting human research subjects. Acad Med 2000; 75: 687-692.
18. Burman W.J., Reves R.R., Cohn D.L., Schooley R.T. Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med 2001, 134: 152-157.
19. US Department of Health and Human Services. Office for Human Research Protections Guidance on continuing review. July 11, 2002. Retrieved 11 February, 2004, from: http://ohrp.osophs.dhhs.gov/humansubjects/guidance/contrev2002.htm%23
20. Morse M.A., Califf R.M., Sugarman J. Monitoring and ensuring safety during clinical research. JAMA 2001; 85: 1201-1205.
21. Ellenberg S.S., George S.L. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Stat Med 2004; in press.
22. Wittes J. Playing safe and preserving integrity: making the FDA model work. Stat Med 2004; in press.
23. Pocock S.J. A major trial needs three statisticians: why, how and who? Stat Med 2004; in press.
24. DeMets D.L., Fleming T.R. The independent statistician for data monitoring committees. Stat Med 2004; in press.
25. Bryant J. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent data monitoring committee in the US cancer cooperative group setting? Stat Med 2004; in press.
26. Siegel J.P., O'Neill R.T., Temple R., Campbell G., Foulkes M.A. Independence of the statistician who analyzes unblinded data. Stat Med 2004; in press.
27. Snapinn S., Cook T., Shapiro D., Snavely D. The role of the unblinded sponsor statistician. Stat Med 2004, in press.
28. Lachin J.M. Management of conflicts in data monitoring of industry versus publicly financed clinical trials. Stat Med 2004; in press.
29. Fisher M., Roecker E.B., DeMets D. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115-129.
30. Packer M., Carver J.R., Rodeheffer R.J., et al. for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. New Engl J Med 1991; 325: 1468-1475.
31. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trials in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
32. Packer M., Coats A.J.S., Fowler M.B., et al. for the Carvedilol Prospective Randomized cumulative Survival (COPERNICUS) Study Group. Effect of Carvedilol on survival in severe chronic heart failure. New Engl J Med 2001; 334: 1651-1658.
33. Dickstein K., Kjekshus J., and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-760.
34. Pitt B., Poole-Wilson P.A., Segal R., et al. on behalf of the ELITE II investigators: effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.